We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+21.1%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow
% of AUM
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| 3 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
DELISTED
Apellis Pharmaceuticals
APLS
| $42.7M | 1.49% |
+468,700
| New | +$40.4M |
2023 Q2
0 quarters
|
|
27
Boston Scientific
BSX
$64B
| $42.5M | 1.48% |
785,700
-64,300
| -8% | -$3.36M |
2022 Q1
5 quarters
|
|
|
28
Ultragenyx Pharmaceutical
RARE
$1.5B
| $41.5M | 1.45% |
900,700
-1,226,200
| -58% | -$56.9M |
2021 Q3
7 quarters
|
|
|
29
Pfizer
PFE
$168B
| $41M | 1.43% |
+1,117,467
| New | +$43.5M |
2023 Q2
0 quarters
|
|
30
Immunovant
IMVT
$5.68B
| $39.6M | 1.38% |
2,085,000
+1,042,000
| +100% | +$19.4M |
2023 Q1
1 quarter
|
|
31
Axsome Therapeutics
AXSM
$8.47B
| $39.2M | 1.37% |
545,000
-74,200
| -12% | -$5.47M |
2022 Q3
3 quarters
|
|
32
DELISTED
Immunogen Inc
IMGN
| $37.7M | 1.32% |
+1,997,800
| New | +$23.6M |
2023 Q2
0 quarters
|
|
33
Zoetis
ZTS
$32.4B
| $37.4M | 1.31% |
217,000
-190,500
| -47% | -$32.9M |
2023 Q1
1 quarter
|
|
34
Prothena Corp
PRTA
$436M
| $36.5M | 1.28% |
535,000
-533,200
| -50% | -$34.4M |
2022 Q3
3 quarters
|
|
35
Vir Biotechnology
VIR
$1.77B
| $35M | 1.22% |
1,425,000
-215,200
| -13% | -$5.4M |
2022 Q4
2 quarters
|
|
36
Immunocore
IMCR
$1.52B
| $34.5M | 1.2% |
575,000
-194,800
| -25% | -$11.1M |
2021 Q1
9 quarters
|
|
37
Sarepta Therapeutics
SRPT
$1.88B
| $34.1M | 1.19% |
297,500
-118,500
| -28% | -$15.3M |
2022 Q3
3 quarters
|
|
38
Arrowhead Research
ARWR
$8.26B
| $33M | 1.15% |
925,000
-816,300
| -47% | -$28.1M |
2021 Q2
8 quarters
|
|
39
Biohaven
BHVN
$1.73B
| $31.7M | 1.11% |
1,325,000
-162,200
| -11% | -$2.79M |
2022 Q4
2 quarters
|
|
40
Revolution Medicines
RVMD
$40.6B
| $28.8M | 1% |
1,075,000
-269,800
| -20% | -$6.62M |
2022 Q2
4 quarters
|
|
41
Privia Health
PRVA
$2.89B
| $28.2M | 0.98% |
+1,079,806
| New | +$28.5M |
2023 Q2
0 quarters
|
|
42
Phathom Pharmaceuticals
PHAT
$607M
| $27.9M | 0.98% |
1,949,700
-98,900
| -5% | -$1.14M |
2021 Q4
6 quarters
|
|
43
Baxter International
BAX
$13.3B
| $27.6M | 0.96% |
+604,700
| New | +$26.3M |
2023 Q2
0 quarters
|
|
44
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $26.6M | 0.93% |
5,700,000
| – | – |
2023 Q1
1 quarter
|
|
45
Rocket Pharmaceuticals
RCKT
$259M
| $26.3M | 0.92% |
1,326,000
+81,600
| +7% | +$1.65M |
2022 Q4
2 quarters
|
|
46
DELISTED
Blueprint Medicines
BPMC
| $26.2M | 0.92% |
+415,000
| New | +$22.6M |
2023 Q2
0 quarters
|
|
47
Editas Medicine
EDIT
$375M
| $24.7M | 0.86% |
+3,000,000
| New | +$26.1M |
2023 Q2
0 quarters
|
|
48
DELISTED
Ventyx Biosciences
VTYX
| $22.7M | 0.79% |
692,500
-1,225,300
| -64% | -$42.2M |
2022 Q4
2 quarters
|
|
49
Natera
NTRA
$58.3B
| $21.1M | 0.74% |
432,900
+183,000
| +73% | +$9.34M |
2020 Q3
11 quarters
|
|
50
Lantheus
LNTH
$6.53B
| $20.6M | 0.72% |
+245,100
| New | +$22M |
2023 Q2
0 quarters
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Miscellaneous.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.